[Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
Takahashi
T
T
Division of Thoracic Disease, Tochigi Cancer Center.
Mori
K
K
Suga
Y
Y
Tominaga
K
K
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D017829:Granisetron; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D007261:Infusions, Intra-Arterial; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D014751:Vindesine / Q000008:administration & dosage; D014839:Vomiting / Q000517:prevention & control*
D000932:Antiemetics; D002945:Cisplatin; D005047:Etoposide; D017829:Granisetron; D007191:Indazoles; D014751:Vindesine